Search results
Moderna’s New Flu-COVID Combi mRNA Vaccine Outperforms Separate Shots In Trials
IFLScience· 3 days agoModerna became a household name thanks to the success of its mRNA vaccine against COVID-19. Along...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 22 hours agoAnd emergency room visits for COVID rose by 16.2% for the week ending June 1. But hospitalizations...
2-in-1 shot for flu and COVID shows promise in advanced trial
Live Science via Yahoo News· 4 days ago(Notably, newer versions of omicron have now overtaken XBB.1.5, so the new vaccine's effectiveness...
New RSV shots tied to rare nervous system disorder — should you worry?
Live Science via Yahoo News· 21 hours agoThere's been some reports of Guillain-Barré syndrome in older adults who got the vaccines. But...
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
NBC Los Angeles· 4 days agoModerna said its combination vaccine targeting Covid and the flu was more effective than existing...
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News· 4 days agoA combination COVID-influenza vaccine is apparently one step closer to hitting the market. Moderna,...
Celebrity doctors promoted Covid vaccine without declaring payments
The Telegraph via Yahoo News· 6 days agoThe pharmaceutical watchdog has been urged to investigate after a string of celebrity doctors took...
Moderna says combination flu, COVID shot succeeds in study
BioPharma Dive via Yahoo Finance· 4 days agoAdvisers to the Food and Drug Administration in March recommended that flu vaccines this year be...
Moderna’s combo COVID and flu vaccine works better than stand-alone shots on the market, study finds
Market Watch· 4 days agoexperimental combination COVID and flu vaccine triggered better immune responses than stand-alone...
FDA clears GSK's RSV vaccine for adults ages 50-59
United Press International via Yahoo News· 6 days agoThe U.S. Food and Drug Administration on Friday approved GSK's respiratory syncytial virus vaccine for high-risk adults ages 50 to 59, expanding the...